Study to Evaluate the Safety, Tolerability and Short Term Efficacy of Extracorporeal Specific Immunoadsorption LupusorbTM Columns for the Treatment of Systemic Lupus Erythematosus (SLE) Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00608127
Recruitment Status : Unknown
Verified May 2008 by Verto LTD.
Recruitment status was:  Active, not recruiting
First Posted : February 6, 2008
Last Update Posted : May 23, 2008
Information provided by:
Verto LTD

Brief Summary:

Systemic Lupus Erythematosus (SLE) is a chronic, autoimmune, inflammatory disease primarily affecting women of childbearing age, and associated with severe morbidity and mortality of its victims. The existing therapy, however, is not specific and its inevitable side effects may themselves be fatal. Therefore, it is a widely recognized need for, and it would be highly advantageous to have a safe, specific rapidly effective and well-defined treatment of SLE, devoid of the disadvantages.

We have shown that VRT101 a peptide present in the extracellular laminin is a target for pathogenic lupus autoantibodies. Using this peptide we have developed the LupusorbTM - an immune-adsorption column which specifically binds pathogenic antibodies from monoclonal cultures as well as from patients` plasma. The investigational product named LupusorbTM Column is a sterile medical device for single use and can be classified into category IIb (synthetic ligands, peptides) according to Annex IX of the European Medical Device Directive 42/93/EEC.

The proposed study, a pilot non-randomized open label study, will test the safety, Tolerability and short term efficacy of a single immunoadsorption procedure in SLE patients.

Condition or disease Intervention/treatment Phase
Systemic Lupus Erythematosus (SLE) Device: LupusorbTM Not Applicable

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Single - Arm Open - Label Study to Evaluate the Safety, Tolerability and Short Term Efficacy of Extracorporeal Specific Immunoadsorption LupusorbTM Columns for the Treatment of Systemic Lupus Erythematosus (SLE) Patients
Study Start Date : January 2007
Estimated Primary Completion Date : May 2008
Estimated Study Completion Date : August 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lupus

Arm Intervention/treatment
Experimental: 1
Single arm open label
Device: LupusorbTM
Single treatment

Primary Outcome Measures :
  1. Safety assessment- Patient's physical examination, vital signs (HR, BP, RR, Rhythm status), lab tests- hematology, CBC & blood biochemistry, Serology panel, anti VRT101 levels, liver and kidney function, urinalysis and SLE serological markers. [ Time Frame: Within 2 months ]

Secondary Outcome Measures :
  1. Efficacy assessment- SLE severity, CBC with differential, ESR, CRP, Blood biochemistry: Serum albumin, Serum Igs, Serology panel: ANA, direct Coomb's; C3, C4, anti-DNA and Serum anti-VRT 101 level and SF 36 Health questionnaire. [ Time Frame: within 2 month ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Participants, either male or female are at least 18 years of age at entry.
  2. Have diagnosed documented SLE, determined at least by 4 criteria as defined by the American Rheumatism Association ARA
  3. Active SLE disease with a SLEDAI score greater than 3
  4. Serum anti-VRT101 at least 0.4 O.D.
  5. Be willing and able to comply with the protocol for the duration of the study.
  6. Participant understands the nature of the procedure and provides written informed consent prior to any study procedure.
  7. If female, must be neither pregnant nor breast-feeding and must lack childbearing potential for the duration of the study.

Exclusion Criteria:

Subjects will be excluded from the study if ANY of the following conditions are present:

  1. Patient has Severe proliferative lupus nephritis:

    1. Rapidly progressive glomerulonephritis (doubling of serum creatinine during last 3 months); or
    2. Severe impairment of renal function Cr more than 2.5 mg/dL
  2. Patient Begin immunosuppressive therapy recently:

    1. Beginning treatment with azathioprine, mycophenolic acid, cyclosporine or methotrexate within 4 weeks.
    2. Cyclophosphamide-an IV pulse within the last 3 months
    3. Pulse therapy with glucocorticoids during the 4 weeks before study entry.
    4. Patient is in on another experimental therapy.
  3. Patient suffers an active or chronic infection.
  4. If female, reports pregnancy, breast-feeding (or inadequate birth control)
  5. Confounding medical illness that in the judgment of investigators would pose.

    Added risk for study participants such as:

    1. Unstable coronary artery disease, cardiomyopathy or dysrhythmia requiring therapy
    2. Hematologic disease (Hb < 7 G/dL, platelets < 50,000/dL or WBC < 2,000/dL).
    3. Bleeding tendency
    4. Hypogammaglobulinemia (Serum IgG< 500mg/dL)
  6. Participation in another clinical trial within 2 months prior to start of this study.
  7. Subject unwilling or unable to comply with the requirements of the protocol.
  8. Any condition that the investigator feels would interfere with trial participation and evaluation of the results.
  9. Subject unwilling and unable to provide inform consent.
  10. Subjects receiving ACE inhibitors treatment 7 days prior to plasmapheresis procedure.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00608127

Hadassah Ein- Kerem
Jerusalem, Israel, 91120
Sponsors and Collaborators
Verto LTD

Additional Information:
Responsible Party: Dr. Anat Scheiman, Hadassah Medical Center Hospital Identifier: NCT00608127     History of Changes
Other Study ID Numbers: LUP-001-ISR
First Posted: February 6, 2008    Key Record Dates
Last Update Posted: May 23, 2008
Last Verified: May 2008

Additional relevant MeSH terms:
Lupus Erythematosus, Systemic
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases